Belviq (lorcaserin) increases risk of depression 1.9-fold

Posted by .(JavaScript must be enabled to view this email address)
Saturday, November 01, 2014 1:28 pm Email this article

Belviq (lorcaserin), a weight loss drug, is associated with a 1.9-fold increase in the risk of depression according to a paper looking at side effects of the drug written by James DiNicolantonio, PharmD and others.

This finding was based on a pooled analysis of three randomized controlled trials testing lorcaserin 10 mg twice daily versus placebo.

Reference

DiNicolantonio JJ, Chatterjee S, O’Keefe JH, and Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart, 2014; 1(1): http://openheart.bmj.com/content/1/1/e000173.full.

Author’s Contact Info

James J. DiNicolantonio, PharmD
Associate Editor BMJ Open Heart
Cardiovascular Research Scientist
Saint Luke’s Mid America Heart Institute
http://www.saintlukeshealthsystem.org/dinicolantonio
https://www.researchgate.net/profile/James_Dinicolantonio
https://twitter.com/jjdinicol
.(JavaScript must be enabled to view this email address)

Articles on the same subject can be found here:

• Belviq (lorcaserin hydrochloride)